Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
CLOVERNA logo — RNA targeted drug discovery

CLOVERNA

RNA targeted drug discovery

Founded 2020 Japan Japan 1 employees Biopharma, Biotechnology +1

General Information

Company Name CLOVERNA
Founded Year 2020
Location Japan Japan
Employees 1
Industries Biopharma, Biotechnology, Pharmaceutical
Social

BounceWatch is an independent company data service, not affiliated with CLOVERNA. To contact CLOVERNA, visit cloverna.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About CLOVERNA

CLOVERNA is a biopharmaceutical company focused on RNA targeted drug discovery. The company's innovative platform utilizes RNA-targeted Drug Discovery technology to identify new RNA databases and drug candidates for treating rare diseases, offering renewed hope to patients. With a mission to uncover previously unavailable biology, CLOVERNA is dedicated to discovering revolutionary medicines and improving human health. The company was founded in 2022 and operates within the biopharma, biotechnology, and pharmaceutical industries. As of now, there is no publicly available information about their headquarters, last investment, or investors.

Taxonomy: Biopharmaceutical, RNA-targeted drug discovery, Rare diseases, Drug discovery platform, RNA databases, Drug candidates, Revolutionary medicines, Healthcare innovation, Biology, Precision medicine

No funding data available for CLOVERNA yet.

CLOVERNA Alternatives & Competitors

CLOVERNA vs
Arrakis Therapeutics
Arrakis Therapeutics United States

Arrakis is on a path to bring powerful new RNA-targeted small molecule (rSM) therapies to millions o...

52 employees
Biopharma, Biotechnology
Compare CLOVERNA vs Arrakis Therapeutics
CLOVERNA vs
RiboNova, Inc.
RiboNova, Inc. United States

Focused on Mitochondrial Disease & other serious rare diseases. R007 is our P2 ready asset, we also...

Venture round
7 employees
Biotechnology, Pharmaceutical
CLOVERNA vs
Santaris Pharma
Santaris Pharma

Pioneering RNA-targeted therapies with rapid LNA-based drug development for diverse disease states.

Venture round
Biotechnology, Health Care

FAQ About CLOVERNA

RNA targeted drug discovery
CLOVERNA was founded in 2020.
CLOVERNA is headquartered in Japan.
CLOVERNA operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on Biopharmaceutical, RNA-targeted drug discovery, Rare diseases and Drug discovery platform.
CLOVERNA has approximately 1 employees.
Top alternatives and competitors to CLOVERNA include Arrakis Therapeutics, RiboNova, Inc., Santaris Pharma, Ventus Therapeutics, Forma Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
CLOVERNA and Arrakis Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for CLOVERNA, https://bouncewatch.com/company/cloverna, updated 21 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes